Indeed, in the imiquimod-psoriasis mouse model, as previously mentioned, TLR7 activation by imiquimod in the skin appears to inhibit adenosine receptors, suggesting a propensity to trigger a stronger immune response during the initial stage of psoriasis [72]. This evidence concerns the gene TLR7 and psoriasis.